Beyond Air, Inc. Material Event: CEO Transition

If you follow Beyond Air, Inc. (ticker: XAIR), you may have seen news about a leadership change. I have broken down exactly what is happening in plain English so you do not have to dig through legal filings.

1. What happened?

Beyond Air announced that CEO Steve Lisi is resigning. He will step down as CEO and leave the Board of Directors on March 27, 2026. Robert (Bob) Goodman, the current Chief Commercial Officer, will take over as the new CEO. Lisi will receive a severance package based on his contract. The Board also granted Goodman 500,000 restricted stock units to align his goals with long-term shareholder value.

2. Why did it happen?

This looks like a strategic shift rather than a reaction to a problem. Steve Lisi led the company for nine years, moving it from a startup to a business with an FDA-approved product, the LungFit PH system.

By choosing Bob Goodman, the company is signaling a move from the "invention" phase to the "sales" phase. Goodman has a strong track record of scaling healthcare businesses at companies like Pfizer, Philips Healthcare, and BioTelemetry. The Board is swapping a "founder-leader" for a "growth-leader" to help get their technology into more hospitals. The company currently spends $8–$10 million per quarter. The Board wants to reach a self-sustaining revenue model to extend their cash beyond the current 18-month projection.

3. Why does this matter?

For Beyond Air, the CEO is the face of the growth strategy.

• The Commercial Signal: Goodman joined the Board in June 2025 and became Chief Commercial Officer in November 2025. His appointment shows the Board supports the "commercial-first" direction he has already been leading. They are targeting a $500 million market for inhaled nitric oxide in the U.S.
• The Background: Goodman is a retired U.S. Army officer. This suggests a focus on disciplined execution—a trait the company needs as it expands in the U.S. and seeks regulatory approvals in Europe and Asia.

4. What should investors know?

• Don't panic: Leadership changes are common. Since this was not a scandal, it is a planned shift in focus.
• Watch the strategy: Look for future press releases. Does the company talk more about hospital contracts and sales numbers? That would confirm the new CEO’s commercial focus. Monitor the "LungFit" adoption rate, which the company aims to grow by 25% each year.
• Stability: The company expects a smooth transition. The existing sales team of about 40 representatives will remain under Goodman’s oversight to ensure continuity.

5. What happens next?

The company is moving forward with its current roadmap. Watch for the next quarterly update, where the new CEO will likely share his specific growth plan. Since Goodman has been with the company for months, he likely has a clear vision. Investors should look for updates on the path to profit, specifically whether they can reach positive earnings by the end of fiscal year 2027.

Investor Bottom Line: This transition is a clear signal that Beyond Air is pivoting from R&D to revenue generation. If you are looking for a "founder-led" story, this is a change in direction. However, if you believe the company’s success now depends on hospital sales and operational efficiency, Goodman’s background makes this a logical—and potentially positive—evolution for the business.